Who will fund hypothesis testing studies?

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7542.666-c (Published 16 March 2006) Cite this as: BMJ 2006;332:666
  1. Mira Harrison-Woolrych, director (Mira.harrison-woolrych@stonebow.otago.ac.nz)
  1. Intensive Medicines Monitoring Programme, University of Otago, Dunedin, New Zealand

    EDITOR—Although Loke et al concluded that case reports in pharmacovigilance have limited value,1 case reports or series are valuable as hypothesis generating papers, which benefit clinicians and patients. The number of follow-up studies is only one outcome by which to judge the value of case reports or series, but other outcomes may be more difficult to study.

    Although case …

    View Full Text

    Sign in

    Log in through your institution